Identification of metabolites of dalfampridine (4-aminopyridine) in human subjects and reaction phenotyping of relevant cytochrome P450 pathways

OBJECTIVES: An extended release formulation of dalfampridine (4-aminopyridine; 4-AP), a potassium channel blocker is available in the USA to improve walking in patients with multiple sclerosis. This study investigated the human metabolites of 4-AP and the cytochrome P450 (CYP450) pathways responsibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Caggiano, Anthony, Blight, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Maney Publishing 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937664/
https://www.ncbi.nlm.nih.gov/pubmed/27536445
http://dx.doi.org/10.3109/21556660.2013.833099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937664/
https://www.ncbi.nlm.nih.gov/pubmed/27536445
http://dx.doi.org/10.3109/21556660.2013.833099

Ejemplares similares